Ramucirumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | VEGFR-2/KDR |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6374H9864N1692O1996S46 |
| Molar mass | 143.6 kDa g·mol−1 |
Ramucirumab (a.k.a.,IMC-1121B) is a monoclonal antibody used in the treatment of solid tumors.
Ramucirumab is a fully-human monoclonal antibody directed against VEGFR2 (KDR). It blocks the binding of vascular endothelial growth factor (VEGF) to its receptor (VEGFR2) and thereby acts as an inhibitor of angiogenesis in the treatment of cancer. In early 2009, the antibody was in a phase III clinical trial for breast cancer, with phase III trials in other solid tumor indications expected to commence shortly. [1]
This drug was developed by ImClone Systems Inc. It was isolated from a Dyax native phage display library.
References
- ^ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - RAMUCIRUMAB, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |